metformin vs Retagliptin/metformin (Ruilintang)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: AMPK · full Type 2 Diabetes pipeline
metformin · Glucophage
Rights held by National Institute of Allergy and Infectious Diseases (NIAID) and partners; US product discontinued
NCT00004992 · Phase 3 · completed
This was a large, randomized, blinded, placebo-controlled trial with a hard clinical endpoint (new diabetes diagnosis), and metformin significantly reduced diabetes incidence versus placebo by 31% (95% CI 17-43%).
Next expected readout: December 2026 · NCT02087826 (registry estimate)
Reported efficacy
Development of diabetes (Up to 5 years): Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%) (met)
Result source: NCT00004992
Retagliptin/metformin (Ruilintang)
Marketed by Jiangsu Hengrui Pharmaceuticals
NCT05415644 · Phase 1 · completed
This is a randomized, blinded, crossover comparison against the reference formulation, which is a sound design for its purpose, but it measures only drug levels in the blood rather than a diabetes outcome, and no results have been posted yet.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | metformin | Retagliptin/metformin (Ruilintang) |
|---|---|---|
| HbA1c, change | 0.2% vs 0.1%+0.1 vs placeboNCT0209983814 other results
| —Not reported |
| Body weight, change (kg) | -0.4 vs -1.1vs MetNCT014388148 other results
| —Not reported |
| HbA1c below 7% | 48.4% vs 45.9%vs LiraglutideNCT011173503 other results
| —Not reported |
| Fasting plasma glucose, change | 0.3 vs 0.0+0.2 vs placeboNCT020998388 other results
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT00004992 | —Not reported |
HbA1c, change
- metformin
- 0.2% vs 0.1%+0.1 vs placeboNCT02099838
14 other results
- -1.0% vs -1.0% NCT01438814
- -0.7% vs -0.9% NCT02049814
- -1.5% vs -0.7% NCT00993187
- -0.9% vs -1.0% NCT01864174
- -1.7% vs -1.1% NCT00751114
- -0.7% vs -0.6% NCT01123980
- 4.1% vs 3.4% NCT01966978
- -0.5% vs -0.3% NCT02429258
- -0.8% vs -0.8% NCT01438814
- -0.3% vs -0.3% NCT01438814
- -0.5% vs -0.6% NCT02049814
- -1.9% vs -1.8% NCT01117350
- -1.3% vs -0.7% NCT01917656
- 1.9% vs 2.3% NCT02007278
- Retagliptin/metformin (Ruilintang)
- —Not reported
Body weight, change (kg)
- metformin
- -0.4 vs -1.1vs MetNCT01438814
8 other results
- 2.0 vs -3.0 NCT01117350
- -1.2 vs -1.4 NCT02049814
- -0.6 vs -0.8 NCT02049814
- -0.0 vs -0.2 NCT02049814
- -0.8 vs 0.9 NCT00993187
- 0.4 vs -1.1 NCT00751114
- -5.4 vs -1.5 NCT01917656
- -0.6 vs 3.1 NCT01966978
- Retagliptin/metformin (Ruilintang)
- —Not reported
HbA1c below 7%
- metformin
- 48.4% vs 45.9%vs LiraglutideNCT01117350
3 other results
- 81.2% vs 40.1% NCT00993187
- 67.9% vs 41.9% NCT00751114
- 44% vs 20% NCT01966978
- Retagliptin/metformin (Ruilintang)
- —Not reported
Fasting plasma glucose, change
- metformin
- 0.3 vs 0.0+0.2 vs placeboNCT02099838
8 other results
- -1.4 vs 0.2 NCT02429258
- -1.4 vs -1.5 NCT01438814
- -2.6 vs -1.3 NCT00993187
- -1.2 vs -1.1 NCT01864174
- -3.6 vs -2.1 NCT01117350
- -3.4 vs -1.1 NCT00751114
- -0.1 vs 0.1 NCT01917656
- -1.8 vs -0.6 NCT01917656
- Retagliptin/metformin (Ruilintang)
- —Not reported
3-point MACE (% with event)
- metformin
- —Not posted · NCT00004992
- Retagliptin/metformin (Ruilintang)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Retagliptin/metformin (Ruilintang): no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. metformin: 4 of 4 rows · Retagliptin/metformin (Ruilintang): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | metformin |
|---|---|
| Dropout rate | 34.4%a NCT01107717 · Phase 4 · registry result, not featured evidence · combination show 39 more results18.7%50mg Bid NCT01528254 · Phase 4 · registry result, not featured evidence · combination 1.3% NCT02561130 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 45% NCT01775813 · Phase 4 · registry result, not featured evidence 22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT01729156 · Phase 4 · registry result, not featured evidence 50%30 mg NCT01972724 · Phase 4 · registry result, not featured evidence —30 mg NCT01972724 · Phase 4 · registry result, not featured evidence 47.4%15 mg NCT01972724 · Phase 4 · registry result, not featured evidence 11.7%0.2 mg NCT02049814 · Phase 4 · registry result, not featured evidence · combination 5.3% NCT01864174 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0.7%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 10% NCT02007278 · Phase 4 · registry result, not featured evidence · combination 8.9%50mg once daily NCT01766778 · Phase 4 · registry result, not featured evidence 6.6%50mg twice daily NCT01766778 · Phase 4 · registry result, not featured evidence 4% NCT02429258 · Phase 4 · registry result, not featured evidence 15.1% NCT01917656 · Phase 4 · registry result, not featured evidence · combination 8.5% NCT02099838 · Phase 4 · registry result, not featured evidence · combination 17.7% NCT00993187 · Phase 4 · registry result, not featured evidence 10.8%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.7%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.2%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —1000 mg Once Daily NCT01842620 · Phase 4 · registry result, not featured evidence 14%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 11.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 8.6%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 4.1%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination —Metformin NCT00820573 · Phase 4 · registry result, not featured evidence —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination 15.2% NCT00751114 · Phase 4 · registry result, not featured evidence 7.3% NCT01123980 · Phase 4 · registry result, not featured evidence 12.8%Glucophage XR in Normal Weight Par NCT00778622 · Phase 4 · registry result, not featured evidence 12.1%Glucophage XR in Obese Participant NCT00778622 · Phase 4 · registry result, not featured evidence 12.3%Glucophage XR in Overweight Partic NCT00778622 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01107717 · Phase 4 · registry result, not featured evidence · combination show 39 more results2.8%50mg Bid NCT01528254 · Phase 4 · registry result, not featured evidence · combination — NCT02561130 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT01775813 · Phase 4 · registry result, not featured evidence — NCT01966978 · Phase 4 · registry result, not featured evidence · combination — NCT01729156 · Phase 4 · registry result, not featured evidence 0%30 mg NCT01972724 · Phase 4 · registry result, not featured evidence —30 mg NCT01972724 · Phase 4 · registry result, not featured evidence 5.3%15 mg NCT01972724 · Phase 4 · registry result, not featured evidence 3.2%0.2 mg NCT02049814 · Phase 4 · registry result, not featured evidence · combination — NCT01864174 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination — NCT02007278 · Phase 4 · registry result, not featured evidence · combination 7.1%50mg once daily NCT01766778 · Phase 4 · registry result, not featured evidence 6.6%50mg twice daily NCT01766778 · Phase 4 · registry result, not featured evidence — NCT02429258 · Phase 4 · registry result, not featured evidence 6.4% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02099838 · Phase 4 · registry result, not featured evidence · combination — NCT00993187 · Phase 4 · registry result, not featured evidence 1.5%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 1.5%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —1000 mg Once Daily NCT01842620 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.3%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 1.2%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 0.9%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination —Metformin NCT00820573 · Phase 4 · registry result, not featured evidence —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination 0.8% NCT00751114 · Phase 4 · registry result, not featured evidence 0.4% NCT01123980 · Phase 4 · registry result, not featured evidence 4%Glucophage XR in Normal Weight Par NCT00778622 · Phase 4 · registry result, not featured evidence 5.6%Glucophage XR in Obese Participant NCT00778622 · Phase 4 · registry result, not featured evidence 3.3%Glucophage XR in Overweight Partic NCT00778622 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 0%a NCT01107717 · Phase 4 · registry result, not featured evidence · combination show 39 more results16.6%50mg Bid NCT01528254 · Phase 4 · registry result, not featured evidence · combination 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT01775813 · Phase 4 · registry result, not featured evidence 11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT01729156 · Phase 4 · registry result, not featured evidence 0%30 mg NCT01972724 · Phase 4 · registry result, not featured evidence 3.9%30 mg NCT01972724 · Phase 4 · registry result, not featured evidence 5.9%15 mg NCT01972724 · Phase 4 · registry result, not featured evidence 1.2%0.2 mg NCT02049814 · Phase 4 · registry result, not featured evidence · combination 2.8% NCT01864174 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 7.2%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0% NCT02007278 · Phase 4 · registry result, not featured evidence · combination 3.6%50mg once daily NCT01766778 · Phase 4 · registry result, not featured evidence 3.3%50mg twice daily NCT01766778 · Phase 4 · registry result, not featured evidence 0% NCT02429258 · Phase 4 · registry result, not featured evidence 1.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT02099838 · Phase 4 · registry result, not featured evidence · combination 5.5% NCT00993187 · Phase 4 · registry result, not featured evidence 3.6%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.6%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.1%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%1000 mg Once Daily NCT01842620 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 2.3%Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence 3.1%Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 0.6%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 0%Metformin NCT00820573 · Phase 4 · registry result, not featured evidence 0%Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination 6.3% NCT00751114 · Phase 4 · registry result, not featured evidence 0.8% NCT01123980 · Phase 4 · registry result, not featured evidence 0.8%Glucophage XR in Normal Weight Par NCT00778622 · Phase 4 · registry result, not featured evidence 0.8%Glucophage XR in Obese Participant NCT00778622 · Phase 4 · registry result, not featured evidence 0%Glucophage XR in Overweight Partic NCT00778622 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | a nausea 25.2% hypoglycemia 13.6% peripheral edema 4.9% NCT01107717 · Phase 4 · registry result, not featured evidence · combination show 33 more results50mg Bid back pain 10.5% (placebo 8.6%) diarrhoea 10.4% (placebo 10.4%) nasopharyngitis 10.4% (placebo 10.8%) NCT01528254 · Phase 4 · registry result, not featured evidence · combination genitourinary infection 5.2% abdominal pain 3.9% injury 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence 300 mg fatigue 3.2% diarrhoea 1.6% discomfort 1.6% NCT03267576 · Phase 4 · registry result, not featured evidence bloating 35% (placebo 29.2%) nausea 35% (placebo 45.8%) diarrhea 30% (placebo 41.7%) NCT01775813 · Phase 4 · registry result, not featured evidence gi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination fractured vertebral column 0% (placebo 8.3%) gastrointestinal uncomfort 0% (placebo 0%) NCT01729156 · Phase 4 · registry result, not featured evidence 30 mg oedema 11.8% eyelid oedema 5.9% folliculitis 5.9% NCT01972724 · Phase 4 · registry result, not featured evidence 30 mg conjunctival haemorrhage 0% eyelid oedema 0% folliculitis 0% NCT01972724 · Phase 4 · registry result, not featured evidence 15 mg conjunctival haemorrhage 5.9% ligament injury 5.9% nasopharyngitis 5.9% NCT01972724 · Phase 4 · registry result, not featured evidence 0.2 mg flatulence 9.3% urinary tract infection 6% NCT02049814 · Phase 4 · registry result, not featured evidence · combination diarrhoea 8.8% NCT01864174 · Phase 4 · registry result, not featured evidence urinary tract infection 1.4% wound infection 0% NCT01845831 · Phase 4 · registry result, not featured evidence · combination influenza like illness 15% headache 10% arthralgia 5% NCT02007278 · Phase 4 · registry result, not featured evidence · combination 50mg once daily upper respiratory tract infection 14.3% cough 3.6% dizziness 3.6% NCT01766778 · Phase 4 · registry result, not featured evidence 50mg twice daily cough 3.3% elevated liver function test 3.3% hyperkalemia 3.3% NCT01766778 · Phase 4 · registry result, not featured evidence urinary tract infection 6% (placebo 6%) NCT02429258 · Phase 4 · registry result, not featured evidence vomiting 5.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination abnormal liver function 13% (placebo 5.9%) hypoglycemia 2.2% (placebo 3.9%) NCT02099838 · Phase 4 · registry result, not featured evidence · combination dyspepsia 13% diarrhoea 10.3% nasopharyngitis 8.9% NCT00993187 · Phase 4 · registry result, not featured evidence influenza 5.7% nasopharyngitis 4.7% diarrhoea 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination headache 5.7% nasopharyngitis 5.7% influenza 2.6% NCT01519674 · Phase 4 · registry result, not featured evidence · combination diarrhoea 5.3% influenza 5.3% headache 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination 1000 mg Once Daily transient headache 4% NCT01842620 · Phase 4 · registry result, not featured evidence 5 mg dyslipidaemia 14% hyperglycaemia 12.7% urinary tract infection 8.9% NCT01512979 · Phase 4 · registry result, not featured evidence 5 mg + Metformin dyslipidaemia 8.8% headache 6.3% urinary tract infection 6.3% NCT01512979 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.9% headache 5% diarrhoea 3.7% NCT01117350 · Phase 4 · registry result, not featured evidence nasopharyngitis 7.5% diarrhoea 3.1% headache 1.3% NCT01117350 · Phase 4 · registry result, not featured evidence 5 mg once daily + metformin once daily diarrhoea 18% abdominal pain 6.7% nausea 6.7% NCT01438814 · Phase 4 · registry result, not featured evidence · combination headache 6.3% influenza 3.4% nasopharyngitis 3.4% NCT00751114 · Phase 4 · registry result, not featured evidence nasopharyngitis 10% NCT01123980 · Phase 4 · registry result, not featured evidence diarrhea 14.4% abdominal distension 4.8% dizziness 4.8% NCT00778622 · Phase 4 · registry result, not featured evidence hyperuricemia 4.8% diarrhea 3.2% dizziness 3.2% NCT00778622 · Phase 4 · registry result, not featured evidence abdominal discomfort 10.7% diarrhea 9.8% abdominal distension 7.4% NCT00778622 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
metformin
show 3 more results
show 1 more result
+ 72 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: metformin's landscape · Retagliptin/metformin (Ruilintang)'s landscape